Resources

At PATH, design thinking is in our DNA. We believe that effective primary health care (PHC) must prioritize people, placing individuals, patients, and caregivers at the forefront of service design and delivery.Through collaboration with partners, PATH is committed to improving PHC nationwide. In Maharashtra's Satara district, PATH has joined forces with the government to pioneer a district-level approach to pilot a replicable model for PHC across the country.To strengthen PHC, we deploy purposeful innovations, integrate disease-specific programs, advance women’s health, incorporate climate-proofing initiatives, and adopt digital advancements to make health care more efficient and accessible.Not only are primary health care centres equipped with new devices and tools, but the PHC benefit package has also been expanded to include communicable and non-communicable diseases, anemia control, and lifesaving care for snakebite envenoming and dog bite.We have mobilized community platforms to foster a culture where health care becomes a collective endeavor. We also assist health centres in obtaining quality certification and improve their supply chain practices.

PATH’s Living Labs Initiative accelerates the pace of health innovation by co-creating with users to rapidly design, test, and scale solutions to their long-standing challenges. We envision a world where all communities have the solutions they need to live healthy lives.

This fact sheet, created by PATH in partnership with AUDA-NEPAD discusses how the African Medicines Agency helps to bring access to safe, effective, quality, and affordable medicines, medical products, and technologies to Africa.

The Pharmaceutical Manufacturing Plan for Africa (PMPA) envisions an Africa where there is significantly reduced reliance on pharmaceutical imports and reduced proliferation of sub-standard and falsified (SF) medical products on the continent. To contribute to the PMPA agenda, the African Medicines Regulatory Harmonization (AMRH) initiative was established through the African Union Development Agency-NEPAD (AUDA-NEPAD), in 2009 and first launched in the East African Community (EAC) in 2012.

While two malaria vaccines are now recommended by the World Health Organization for use in African children, there remains a need for next-generation vaccines that are more efficacious, durable, and cost-effective, and that require fewer doses.One promising approach is the development of multistage vaccines targeting both the pre-erythrocytic and asexual blood stages of the malaria parasite’s lifecycle. In May 2023, under the Innovations in Malaria Vaccine Development contract, the US Agency for International Development’s Malaria Vaccine Development Program and PATH convened a panel of experts in malaria, vaccine development, regulatory affairs, and the conduct of clinical trials in Africa, Europe, and the United States to consider and inform the development of a comprehensive clinical development plan for a multistage malaria vaccine.This report summarizes the discussions held during the consultation and outlines the experts' key recommendations to inform a clinical development plan.